从全球哮喘管理和预防战略指南治疗策略的变迁对2型炎症型哮喘管理的浅析  

Analysis on the management of type 2 inflammatory asthma from the guideline of Global Strategy for Asthma Management and Prevention

作　　者：关文超 柴若楠 许翀 王新琢 黄荷花 赵雨萌 邹红梅 Guan Wenchao;Chai Ruonan;Xu Chong;Wang Xinzhuo;Huang Hehua;Zhao Yumeng;Zou Hongmei(Department of Respiratory Medicine,General Hospital of the Northern Theater Command of the Chinese People′s Liberation Army,Shenyang 110016,China)

机构地区：[1]中国人民解放军北部战区总医院呼吸内科,沈阳110016

出　　处：《中华预防医学杂志》2023年第12期1964-1971,共8页Chinese Journal of Preventive Medicine

摘　　要：支气管哮喘是常见的慢性呼吸道疾病,由多种细胞及细胞组分参与。2019年,全球哮喘倡议(Global Initiative for Asthma,GINA)委员会发布的哮喘诊治指南首次提出2型炎症型哮喘的概念。GINA指南的更新演变推动了生物制剂的研发和疾病治疗,为重度哮喘患者提供有效的预防和治疗手段并改善疾病转归。本文阐述了GINA指南中2型炎症型哮喘的疾病机制及管理建议,分析了近年来2型炎症型哮喘靶向治疗的相关临床研究,以期为深入了解2型炎症型哮喘患者的3级预防管理提供参考。Bronchial asthma is a common chronic respiratory disease,which is involved in a variety of cells and cellular components.In 2019,the guidelines for the diagnosis and treatment of asthma issued by the Global Initiative for Asthma(GINA)Committee put forward the concept of type 2 inflammatory asthma for the first time.The updated evolution of GINA guidelines has promoted the development of biological agents and disease treatment,providing effective prevention and treatment for patients with severe asthma and improving disease outcome.This paper expounds the disease mechanism and management suggestions of type 2 inflammatory asthma in GINA guidelines,and analyzes the relevant clinical studies on targeted treatment of type 2 inflammatory asthma in recent years,in order to provide reference for in-depth understanding of level 3 prevention and management of patients with type 2 inflammatory asthma.

关 键 词：2型炎症 支气管哮喘 生物制剂 免疫 靶向治疗 

分 类 号：R562.25[医药卫生—呼吸系统]